Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

BioLineRx begins phase I/II trial of BL-7010 in celiac disease

Dec. 19, 2013

Amgen reports topline results from phase III MENDEL-2 trial

Dec. 19, 2013

Boehringer Ingelheim patents new GPR40 agonists for diabetes

Dec. 18, 2013

Chinese researchers prepare new SGLT2 inhibitors for diabetes

Dec. 18, 2013

Alnylam begins phase II study of ALN-TTRsc for transthyretin-mediated amyloidosis

Dec. 17, 2013

Astrazeneca reports topline results from phase III study of lesinurad in gout

Dec. 17, 2013

FDA advisory committee recommends approval of dapagliflozin

Dec. 16, 2013

SPX-106T lowers cholesterol and triglyceride levels and prevents weight gain in vivo

Dec. 16, 2013

Korean researchers present new antibodies that bind to RANKL for bone disorders

Dec. 16, 2013

FDA committee recommends approval of metreleptin for generalized lipodystrophy

Dec. 13, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...